Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...
RBC Capital Markets thinks CSL is a bargain at current levels. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool ...
CSL Behring's Andembry can be used to prevent recurrent attacks of hereditary angioedema (HAE) by the NHS, according to finalised guidance from reimbursement authority NICE. The just-published ...
This ASX heavyweight has potential to deliver superior returns but is more volatile. CSL remains the crown jewel of the ASX healthcare sector. Its plasma therapies, vaccines, and biologics underpin a ...
Carlisle Companies is well-positioned to benefit from a projected rebound in U.S. residential construction driven by lower interest and mortgage rates in 2026. CSL’s revenue mix, with 74% from ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results